Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Tenaris Q1 2026 Earnings Call - Geopolitical Turmoil Tests Supply Chains While North America and Offshore Backlogs Point to Stronger Second Half
Tenaris reported a resilient first quarter with sales rising 6% year-over-year to $3.1 billion and net income jumping 22% to $564 million, despite the sudden closure of the Strait of Hormuz disrupting...
- Sales rose 6% year-over-year to $3.1 billion in Q1 2026, defying Middle East disruptions.
- Net income jumped 22% to $564 million, driven by lower tariff costs and better below-the-line results.
- EBITDA margin held steady at 24%, as higher maintenance costs were offset by tariff savings.
- +7 more takeaways
Celsius Holdings Q1 2026 Earnings Call - Record Revenue Hits $783M as Alani Nu Integration Cuts Costs and Margin Trajectory Holds
Celsius Holdings delivered a record $783 million in first quarter revenue, driven by a 60% surge in Alani Nu sales and steady Celsius performance. The company completed the Alani Nu integration, captu...
- Record first quarter revenue of $783 million, setting a new quarterly high for Celsius Holdings.
- Alani Nu net sales surged 60% year-over-year to $368 million, reflecting strong execution post-acquisition.
- Celsius brand net sales grew approximately 6% year-over-year to $348 million, supported by SKU optimization and Fizz-Free expansion.
- +7 more takeaways
Kulicke and Soffa Q2 2026 Earnings Call - Advanced Packaging Demand Surges as TCB Revenue Exceeds $100M
Kulicke and Soffa delivered a standout second quarter for fiscal 2026, with revenue jumping 21.5% sequentially to nearly $275 million, driven by a sharp rebound in memory shipments and robust demand f...
- Revenue surged 21.5% sequentially in Q2 FY2026, driven by a 93% jump in memory shipments and strong general semiconductor demand.
- Thermal compression bonding (TCB) revenue is on track to exceed $100 million for the full fiscal year, growing at least 70% sequentially.
- Management announced plans to expand Advanced Solutions production capacity to support approximately $400 million in annual revenue, with $12 million in capital expenditures allocated in FY2026.
- +7 more takeaways
Somnigroup International Q1 2026 Earnings Call - EBITDA Margins Expand as Mattress Firm Synergies Drive Profitability
Somnigroup International delivered a resilient first quarter in 2026, with net sales rising 12% to $1.8 billion and adjusted EBITDA jumping 20% to $297 million. The results underscore the operating le...
- Net sales grew 12% to $1.8 billion, with adjusted EBITDA rising 20% to $297 million, driven by strong operating leverage and cost discipline.
- Adjusted EPS increased 20% to $0.59 per share, reflecting a 100+ basis point expansion in EBITDA margins despite a challenging macro environment.
- Global bedding demand declined mid-single digits in Q1, but Somnigroup outperformed the market across all major segments, including North America, International, and Mattress Firm.
- +12 more takeaways
1-800-FLOWERS.COM, Inc. Q3 FY2026 Earnings Call - Cost Savings Ahead of Plan, Marketing Pivot Begins
1-800-FLOWERS.COM is stabilizing. Revenue fell 11.6% in Q3 FY2026, dragged by an 18.7% plunge in Consumer Floral & Gifts, but the company hit its $50 million cost savings target a year early. Manageme...
- Revenue declined 11.6% year-over-year, with Consumer Floral & Gifts down 18.7% and Gourmet Foods & Gift Baskets essentially flat.
- Company achieved its $50 million annualized cost savings target ahead of schedule, with an additional $15-20 million in savings targeted for the next fiscal year.
- Management is pivoting marketing strategy from bottom-funnel transactional spending to top and mid-funnel brand building, including influencer marketing on TikTok and Instagram.
- +7 more takeaways
Ispire Technology Q3 2026 Earnings Call - Cash Flow Inflection Point and Malaysia Manufacturing Advantage
Ispire Technology reported a revenue dip to $18.7 million for fiscal Q3 2026, but management framed the quarter as a decisive turning point in the company’s restructuring. Sequential cash grew by $468...
- Revenue declined to $18.7 million in fiscal Q3 2026, down from $26.2 million year-over-year, though the sequential drop was only 8%, marking the most resilient second-to-third quarter performance in company history.
- Sequential cash growth of $468,000 brought the cash balance to $18 million, reinforcing management’s confidence in reaching cash flow positivity in the second half of calendar 2026.
- Gross margin stood at 10.7%, with gross profit negatively impacted by $2.2 million in one-time product returns from a legacy cannabis customer no longer in the supply chain.
- +7 more takeaways
Collegium Pharmaceutical Q1 2026 Earnings Call - AZSTARYS Acquisition Accelerates ADHD Growth
Collegium Pharmaceutical reported a strong start to 2026, driven by a 36% year-over-year surge in Jornay PM net revenue to $38.9 million and a durable 4% growth in its pain portfolio. The company succ...
- Jornay PM net revenue surged 36% year-over-year to $38.9 million, driven by a 14% increase in prescriptions and a 17% expansion in the prescriber base to an all-time high of 30,000.
- The company announced a $650 million cash acquisition of AZSTARYS, a differentiated ADHD treatment, which is expected to close in the second quarter of 2026 after the Hart-Scott-Rodino waiting period expired.
- Total pain portfolio net revenues grew 4% year-over-year to $154.6 million, with BELBUCA up 2% and XTAMPZA ER up 7%, providing a stable cash flow foundation for the business.
- +9 more takeaways
Evolent Health Q1 2026 Earnings Call - Strong Q1 Execution Masks Exchange Headwinds, Performance Suite Dominates Growth
Evolent Health delivered a solid first quarter, with revenue of $496 million and adjusted EBITDA of $22 million, landing in line with expectations. The core narrative is one of disciplined execution a...
- Revenue of $496 million grew 9% sequentially (ex-ECP), while adjusted EBITDA came in at $22 million, meeting expectations.
- Medical Expense Ratio (MER) improved 150 basis points to 93%, supported by favorable prior year development that offset higher oncology prevalence.
- Performance Suite revenue surged 26% sequentially to $323 million, driven by the new Aetna launch and membership growth.
- +7 more takeaways
Primo Brands Q1 2026 Earnings Call - Direct Delivery Turnaround Drives Raised Growth Guidance
Primo Brands delivered a strong start to 2026, with first quarter comparable net sales rising 1.7% to $1.63 billion, driven by broad-based price mix and volume gains. The company raised its full year ...
- Comparable net sales grew 1.7% year-over-year to $1.63 billion, marking a return to top-line growth driven by price mix and volume.
- Full year comparable organic net sales guidance raised to 1%-3% from flat to 1%, reflecting stronger-than-expected first quarter performance.
- Direct delivery service levels improved significantly, with on-time-in-full rates exceeding 90% and customer net adds approaching breakeven in March.
- +7 more takeaways
Teleflex Q1 2026 Earnings Call - Divestitures on Track, New CEO Hired, and Margin Pressure from Recalls
Teleflex delivered a mixed first quarter, with revenue growth beating expectations but adjusted EPS falling as margin pressure mounted from tariffs and a third-party supplier recall. The company is ex...
- Teleflex Q1 2026 revenue grew 5.1% on a pro forma adjusted constant currency basis to $548.3 million, beating internal expectations and tracking within the 4.5%-5.5% full-year guidance range.
- Adjusted EPS fell 3.5% year-over-year to $1.39 due to margin pressure from tariffs, higher interest expense, and quality remediation charges linked to a third-party supplier recall.
- The company announced the appointment of Jason Weidman as the next President and CEO, effective June 8, 2026, bringing over 25 years of medical technology experience from Medtronic.
- +7 more takeaways